Compare CRNX & DRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | DRD |
|---|---|---|
| Founded | 2008 | 1895 |
| Country | United States | South Africa |
| Employees | N/A | 3410 |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.4B |
| IPO Year | 2018 | N/A |
| Metric | CRNX | DRD |
|---|---|---|
| Price | $33.65 | $28.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $74.78 | $32.63 |
| AVG Volume (30 Days) | ★ 1.0M | 327.1K |
| Earning Date | 05-07-2026 | 08-19-2026 |
| Dividend Yield | N/A | ★ 2.16% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $722.66 | $34.35 |
| Revenue Next Year | $183.79 | $24.62 |
| P/E Ratio | ★ N/A | $15.32 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.10 | $13.08 |
| 52 Week High | $57.99 | $39.37 |
| Indicator | CRNX | DRD |
|---|---|---|
| Relative Strength Index (RSI) | 29.20 | 38.62 |
| Support Level | $33.23 | $25.95 |
| Resistance Level | $37.23 | $30.40 |
| Average True Range (ATR) | 1.62 | 1.19 |
| MACD | 0.13 | -0.28 |
| Stochastic Oscillator | 8.33 | 24.89 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.